Profile of teriparatide in the management of postmenopausal osteoporosis

Review

(2617) Views  (834) Full article downloads

Authors: Andrea Sikon, Pelin Batur

Published Date March 2010 Volume 2010:2 Pages 37 - 44

DOI: http://dx.doi.org/10.2147/IJWH.S4919

Andrea Sikon¹, Pelin Batur²

¹Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA; ²Cleveland Clinic Lerner COM, Cleveland Clinic Independence, Independence, OH, USA

Abstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.

Keywords: osteoporosis, menopause, teriparatide